Innumerous data support the fact that insulin-degrading enzyme (IDE) is the primary enzymatic mechanism for initiating and controlling cellular insulin degradation. Nevertheless, insulin degradation is unlikely to be the only cellular function of IDE, because it appears that some cellular effects of insulin are mediated by IDE as a regulatory protein. Insulin-degrading enzyme shows a significant correlation with various cellular functions, such as cellular growth and differentiation, and the expression of IDE is developmentally regulated. Besides insulin, other substrates are also degraded by IDE, including various growth-promoting peptides. It has also been shown that IDE enhances the binding of androgen to DNA in the nuclear compartment. It is also known that the androgen hormones have a stimulatory effect on prostate growth, and that estradiol stimulates uterine growth. To establish whether IDE is regulated by a cellular prostate/uterine growth stimulus, the present study assessed whether IDE was modified in quantity and activity during proliferative conditions (castration + testosterone in the male rat, or castration + estradiol or the proestrus phase of the estrous cycle in the female rat) and autolysis (castration or the metestrus phase of the estrous cycle) using cytosolic and nuclear fractions of rat prostate and cytosolic fractions of rat uterus. The activity and amount of IDE decreased in the cytosolic fraction with castration and during metestrus, and increased with testosterone or estradiol treatment and during proestrus. In the nuclear fraction, the quantity of the IDE followed the same pattern observed in the cytosolic fraction, although without degradative activity. The data presented here suggest that IDE may participate in prostatic and uterine growth and that the testosterone or estradiol and/or prostate and uterus insulin-like growth factors may be important factors for the expression and regulation of IDE in the prostate and uterus
UdrisarDP, WanderleyMI. Fluoride and phosphatidylserine-induced inhibition of cytosolic insulin-degrading activity. Acta Physiol Pharmacol Latinoam42: 183–193, 1992.
4.
MisbinRI, AlmiraEC, DuckworthWC, MehlTD. Inhibition of insulin degradation by insulin-like growth factors. Endocrinology113: 1525–1527, 1983.
5.
GarciaJV, GehmBD, RosnerMR. An evolutionarily conserved enzyme degrades transforming growth factor-alpha as well as insulinJ Cell Biol109:1301–1307, 1989.
6.
GehmBD, RosnerMR. Regulation of insulin, epidermal growth factor, and transforming growth factor-α levels by growth factor degrading enzymes. Endocrinology128: 1603–1609, 1991.
7.
CrossM, DexterTM. Growth factors in development, transformation and tumorigenesis. Cell64: 271–280, 1991.
8.
KupferS, MarschkeK, WilsonEM, FrenchFS. Receptor accessory factor enhances specific DNA binding of androgen and glucocorticoid receptorsJ Biol Chem268:17519–17527, 1993.
9.
KuoWL, MontagAG, RosnerMR. Insulin-degrading enzyme is differentially expressed and developmentally regulated in various rats tissues. Endocrinology132: 604–611, 1993.
10.
BlondeauJP, BaulieuEE, RobelP. Androgen-dependent regulation of androgen nuclear receptor in the rat ventral prostate. Endocrinology110: 1926–1932, 1982.
11.
DuckworthWC, HeinemannMA, KitabchiAE. Purification of insulin-specific protease by affinity chromatography. Proc Nat Acad Sci U S A69: 3698–3702, 1972.
12.
UdrisarD, RodbellM. Microsomal and cytosolic fractions of guinea pig hepatocytes contain 100-kilodalton GTP-binding proteins reactive with antisera against alpha subunits of stimulatory and inhibitory heterotrimeric GTP-binding proteinsProc Natl Acad Sci U S A87:6321–6325, 1990.
13.
LaemmliUK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature227: 680–685, 1970.
14.
BaumeisterH, MullerD, RebbeinM, RitcherD. The rat insulin-degrading enzyme: molecular cloning and characterization of tissue-specific transcripts. FEBS Lett317: 250–254, 1993.
15.
CrestoJC, UdrisarDP, CamberosMC, BasabeJC, Gomez AcuñaP, de MajoSF. Preparation of biologically active mouo-125I-insulin of high specific activity. Acta Physiol Latinoam31: 13–24, 1981.
16.
UdrisarDP, CamberosMC, BasabeJC, CrestoJC. Insulin processing Its correlation with glucose conversion to CO2. Acta Physiol Pharmacol Latinoam34: 427–440, 1984.
17.
BradfordMM. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem72: 248–254, 1976.
18.
CunhaGR, DonjacourAA, CookePS, MeeS, BigsbyRM, HigginsSJ, SugimuraY. The endocrinology and developmental biology of the prostate. Endocr Rev8: 338–362, 1987.
19.
SteinerMS. Role of peptide growth factors in the prostate: a review. Urology42: 99–110, 1993.
20.
LopaczynskiW, HruszkewyczAM, LiebermanR. Preprostatectomy: a clinical model to study stromal-epithelial interactions. Urology57(Suppl 4A):194–199, 2001.
21.
CunhaGR. Growth factors as mediators of androgen action during male urogenital development. Prostate6: 22–25, 1996.
22.
CuligZ, HobischA, CronauerMV, RadmayrC, HittmairA, ZhangJ, ThurnherM, BartschG, KlockeH. Regulation of prostatic growth and function by peptide growth factors. Prostate28: 392–405, 1996.
23.
CohenP, PeehlDM, LamsonG, RosenfeldRG. Insulin-like growth factors IGFs, IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab73: 401–407, 1991.
24.
ByrneRL, LeungH, NealDE. Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Br J Urol77: 627–633, 1996.
25.
MisbinRI, AlmiraEC. Degradation of insulin and insulin-like growth factors by enzyme purified from human erythrocytes. Comparison of degradation products observed with A14- and B26-[125I]monoiodoinsulin. Diabetes38: 152–157, 1989.
26.
BondyCA, ZhouJ, ChinE, ReinhardtRR, RothRA. Cellular distribution of insulin-degrading enzyme gene expression: comparison with insulin and insulin-like growth factor receptors. J Clin Invest93: 966–973, 1994.
27.
NishiN, OyaH, MatsumotoK, NakamuraT, MiyankaH, WadaF. Changes in gene expression of growth factors and their receptors during castration-induced involution and androgen-induced regrowth of rat prostate. Prostate28: 139–152, 1996.
28.
NickersonT, PollakM, HuynhH. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2, 3, 4 and 5. Endocrinology139: 807–810, 1998.
29.
KupferS, WilsonEM, FrenchFS. Androgen and glucocorticoid receptors interact with insulin degrading enzyme. J Biol Chem269: 20622–20628, 1994.
30.
HaradaS, SmithRM, JarettL. Mechanisms of nuclear translocation of insulin. Cell Biochem Biophys313: 307–219, 1999.
31.
DuckworthWC, BennettRG, HamelFG. The significance of intracellular insulin to insulin action. J Invest Med45: 20–27, 1997.
32.
SatoT, FukazawaY, KojimaH, EnariM, IguchiT, OhtaY. Apoptotic cell death during the estrous cycle in the rat uterus and vagina. Anat Rec248: 76–83, 1997.
33.
ButcherRL, CollinsWE, FugoNW. Plasma concentration of LH, FSH, prolactin, progesterone and estradiol-17beta throughout the 4-day estrous cycle of the rat. Endocrinology946: 1704–1708, 1974.
34.
ShelesnyakMC, TicL. Studies on the mechanism of nidation. V. Superession of synthetic processes of the uterus DNA, RNA e protein following inhibition of decidualization by na antiestrogen, ethamoxytriphetol MER-25. Acta Endocrinol43: 462–468, 1963.
35.
MarcusGJ. Mitosis in the rat uterus during the estrous cycle, early pregnancy, and early pseudopregnancy. Biol Reprod10: 447–452, 1974.
36.
MurphyLJ, GhaharyA. Uterine insulin-like growth factor-1: regulation of expression and its role in estrogen-induced uterine proliferation. Endocr Rev11: 443–453, 1990.
37.
BrigstockDR. Growth factors in the uterus: steroidal regulation and biological actions. Baillieres Clin Endocrinol Metab5: 791–808, 1991.
38.
RichardsRG, DiAugustineRP, PetruszP, ClarkGC, SebastianJ. Estradiol stimulates tyrosine phosphorylation of the insulin-like growth factor-1 receptor and insulin receptor substrate-1 in the uterus. Proc Natl Acad Sci U S A9321: 12002–12007, 1996.
39.
GiudiceLC, MarkSP, IrwinJC. Paracrine actions of insulin-like growth factors and IGF binding protein-1 in non-pregnant human endometrium and at the decidual-trophoblast interface. J Reprod Immunol39: 133–148, 1998.
40.
CollinsBM, McLachlanJA, ArnoldSF. The estrogenic and antiestrogenic activities of phytochemicals with the human estrogen receptor expressed in yeast. Steroids62: 365–372, 1997.
41.
PerezA, MorelliL, CrestoJC, CastanoEM. Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem Res252: 247–255, 2000.
42.
FarrisW, MansourianS, ChangY, LindsleyL, EckmanEA, FroschMP, EckmanCB, TanziRE, SelkoeDJ, GuenetteS. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A1007: 4162–4167, 2003.
43.
GourasGK, XuH, GrossRS, GreenfieldJP, HaiB, WangR, GreengardP. Testosterone reduces neuronal secretion of Alzheimer's β-amyloid peptides. Proc Natl Acad Sci U S A97: 1202–1205, 2000.
PetanceskaSS, NagyV, FrailD, GandyS. Ovariectomy and 17beta-estradiol modulate the levels of Alzheimer's amyloid beta peptides in brain. Neurology5412: 2212–2217, 2000.
46.
CamberosMC, PerezAA, UdrisarDP, WanderleyMI, CrestoJC. ATP inhibits insulin-degrading enzyme activity. Exp Biol Med (Maywood)2264: 334–341, 2001.
